ATE346863T1 - Verwendung von eif4e-bindungsreagenzien in der therapie - Google Patents

Verwendung von eif4e-bindungsreagenzien in der therapie

Info

Publication number
ATE346863T1
ATE346863T1 AT00940589T AT00940589T ATE346863T1 AT E346863 T1 ATE346863 T1 AT E346863T1 AT 00940589 T AT00940589 T AT 00940589T AT 00940589 T AT00940589 T AT 00940589T AT E346863 T1 ATE346863 T1 AT E346863T1
Authority
AT
Austria
Prior art keywords
therapy
binding reagents
eif4e binding
eif4e
xxyxxx
Prior art date
Application number
AT00940589T
Other languages
English (en)
Inventor
Christopher Gregory Proud
Terrence Patrick Herbert
David Philip Lane
Robin Fahraeus
Original Assignee
Univ Dundee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Dundee filed Critical Univ Dundee
Application granted granted Critical
Publication of ATE346863T1 publication Critical patent/ATE346863T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT00940589T 1999-06-21 2000-06-21 Verwendung von eif4e-bindungsreagenzien in der therapie ATE346863T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9914480.0A GB9914480D0 (en) 1999-06-21 1999-06-21 Use of peptides

Publications (1)

Publication Number Publication Date
ATE346863T1 true ATE346863T1 (de) 2006-12-15

Family

ID=10855771

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00940589T ATE346863T1 (de) 1999-06-21 2000-06-21 Verwendung von eif4e-bindungsreagenzien in der therapie

Country Status (7)

Country Link
US (1) US7141541B1 (de)
EP (1) EP1189936B1 (de)
JP (1) JP2003502440A (de)
AT (1) ATE346863T1 (de)
DE (1) DE60032143D1 (de)
GB (1) GB9914480D0 (de)
WO (1) WO2000078803A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144190A1 (en) * 1999-12-02 2003-07-31 Nahum Sonenberg Method of modulating and antiapoptotic and antiapoptotic pathways in cells
US6759394B2 (en) 2001-07-26 2004-07-06 Board Of Supervisors Of La. State Un. & Agricultural And Mechanical College Cancer gene therapy based on translational control of a suicide gene
WO2009083188A2 (en) * 2007-12-28 2009-07-09 Fovea Pharmaceuticals Compositions and methods for prophylaxis and treatment of cellular degenerative disorders
FR2942798B1 (fr) * 2009-03-05 2011-04-08 Centre Nat Rech Scient Peptides utilisables pour le traitement de la leucemie lymphoide chronique
EP2569327B1 (de) * 2010-04-27 2016-05-25 Agency For Science, Technology And Research Eif4e-bindende peptide
EP2870174A1 (de) 2012-07-09 2015-05-13 F. Hoffmann-La Roche AG Zellenpenetrierende, gegen eif4e gerichtete peptide
TW202114681A (zh) 2019-07-02 2021-04-16 美商ｅＦＦＥＣＴＯＲ醫療公司 轉譯抑制劑及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994018345A1 (en) 1993-02-05 1994-08-18 Affymax Technologies N.V. Receptor-binding antiproliferative peptides
US5622852A (en) 1994-10-31 1997-04-22 Washington University Bcl-x/Bcl-2 associated cell death regulator
WO1998039357A1 (en) 1997-03-05 1998-09-11 The Regents Of The University Of California Method of alleviating neuropathic pain
US6610508B1 (en) * 1999-03-08 2003-08-26 Anadys Pharmaceuticals, Inc. Translation driver system and methods for use thereof

Also Published As

Publication number Publication date
WO2000078803A2 (en) 2000-12-28
GB9914480D0 (en) 1999-08-18
EP1189936A2 (de) 2002-03-27
JP2003502440A (ja) 2003-01-21
EP1189936B1 (de) 2006-11-29
DE60032143D1 (de) 2007-01-11
WO2000078803A3 (en) 2001-07-26
US7141541B1 (en) 2006-11-28

Similar Documents

Publication Publication Date Title
ATE159429T1 (de) Methode zum überbringen von agenzien an zielzellen
DK0572688T3 (da) Peptider, med organ-beskyttende aktivitet, fremgangsmåde til deres fremstilling og deres anvendelse ved terapi
IL77748A (en) Amino acid and peptide derivatives as peptidase inhibitors
ATA260690A (de) Therapeutische infusionszubereitung auf basis von aminosäurederivaten
ATE354638T1 (de) Menschlicher gewebsinhibitor von metalloproteinase-4
ATE257859T1 (de) Humanes, rekombinantes interferon-beta mit verbesserter löslichkeit
ATE125706T1 (de) Diphosphonate enthaltende pharmazeutische zusammensetzungen zur behandlung von arthrosis.
ATE346863T1 (de) Verwendung von eif4e-bindungsreagenzien in der therapie
ATE393631T1 (de) Peptid und dessen kosmetische oder dermatologische verwendung zur verbesserung der haftung zwischen hautzellen
NO980299D0 (no) Cytokinproduksjonsinhibitorer, preparater derav og deres anvendelse i medisin, samt fremgangsmåter for deres identifikasjon
DK398986D0 (da) Aminosyrederivater, fremgangsmaade til deres fremstilling og deres anvendelse
FI964186A0 (fi) Ei-liittävät gp350/220-variantit
NO20000814L (no) Identifikasjon for klebende flateformede dermale og transdermale terapeutiske administrasjonsformer under anvendelse av et klebende plaster som informasjonsbærer, såvel som fremgangsmåte for deres fremstilling
EE200000102A (et) Meetodid ja kompositsioonid teraapiaks, kasutades sekreteeritavaid valke, näiteks interferoon-beetat kodeerivaid geene
DK26589D0 (da) Aminosyreglycerider og fysiologisk acceptable salte deraf med syrer og baser, deres fremstilling og anvendelse
FR2766190B1 (fr) Nouveaux peptides et polypeptides utiles dans la regeneration du systeme nerveux
NO873437L (no) Human placenta angiogen faktor i stand til aa stimulere kapillaer endotelcelle-proteasesyntese, dna-syntese og migrasjon.
ES8900018A1 (es) Procedimiento para la fabricacion de derivados aminoalcoholes peptidicos inhibidores de la renina y de las proteasas acidas
FI901876A7 (fi) Epätäydelliset hepadnavirukset, rokotteita tuottavat solulinjat sekä m aksan sairauksien hoito
NO890174L (no) Rekombinante interleukin-1alfa-polypeptider.
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
DK513188A (da) Aminosyreestre, deres fremstilling og anvendelse som laegemidler
DE69821227D1 (de) Verwendung von papovavirus kapsid-proteinen zur verabreichung therapeutischen agentien in nervzellen
NO891653D0 (no) Aminosyreestere og deres fremstilling.
DK0811068T3 (da) Humane DNase I varianter

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties